Abstract Background Immune checkpoints inhibitors (ICIs) have emerged as a treatment
option for several malignancies. Nivolumab, pembrolizumab, nivolumab plus ipilimumab …

Hepatocellular carcinoma (HCC) is the most common primary neoplasia of the liver. There
have been tremendous efforts in the development of therapeutic strategies in the last …

Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation:
The silver bullet? Page 1 Pembrolizumab for Metastatic Hepatocellular Carcinoma Following …

Background: Immune checkpoint blockade has revolutionized the treatment of multiple
malignancies. Currently, however, the effect is not universal, with objective response rates …

Background Vascular endothelial growth factor (VEGF) plays a role in the tumor
microenvironment. Sorafenib, which inhibits the VEGF pathway, has an immune-modulation …

Objective Camrelizumab is a newly developed program-death receptor one inhibitor; the
real-world evidence about its application in hepatocellular carcinoma (HCC) treatment is …

Hepatocellular carcinoma (HCC) is one of the most common types of cancer globally and is
currently the third leading cause of cancer-related deaths. Recently, immunotherapy using …

Ovarian cancer (OC) is associated with poor survival because there are a limited number of
effective therapies. Two processes key to OC progression, angiogenesis and immune …

Despite clinical studies with different mechanisms of action, no new systemic therapies were
approved for hepatocellular carcinoma (HCC) between sorafenib in 2007 and regorafenib in …

Background The recently proposed nomogram of Barcelona Clinic Liver Cancer (BCLC)
lacks predictive accuracy for patients with stage D hepatocellular carcinoma (HCC). Tumor …